Baxter International Inc (BAX) Holdings Trimmed by Bartlett & Co. LLC

Bartlett & Co. LLC decreased its holdings in Baxter International Inc (NYSE:BAX) by 2.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 555,623 shares of the medical instruments supplier’s stock after selling 15,356 shares during the period. Baxter International comprises approximately 1.4% of Bartlett & Co. LLC’s holdings, making the stock its 22nd largest holding. Bartlett & Co. LLC owned approximately 0.10% of Baxter International worth $35,915,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in BAX. Parametric Portfolio Associates LLC increased its stake in Baxter International by 71.1% in the second quarter. Parametric Portfolio Associates LLC now owns 1,632,846 shares of the medical instruments supplier’s stock worth $98,852,000 after purchasing an additional 678,429 shares during the period. Acadian Asset Management LLC increased its stake in Baxter International by 156.7% in the fourth quarter. Acadian Asset Management LLC now owns 657,855 shares of the medical instruments supplier’s stock worth $42,523,000 after purchasing an additional 401,532 shares during the period. Canada Pension Plan Investment Board increased its stake in Baxter International by 35.8% in the third quarter. Canada Pension Plan Investment Board now owns 1,413,054 shares of the medical instruments supplier’s stock worth $88,669,000 after purchasing an additional 372,500 shares during the period. Segall Bryant & Hamill LLC increased its stake in Baxter International by 209.0% in the third quarter. Segall Bryant & Hamill LLC now owns 412,054 shares of the medical instruments supplier’s stock worth $25,856,000 after purchasing an additional 278,685 shares during the period. Finally, Nordea Investment Management AB increased its stake in Baxter International by 619.2% in the third quarter. Nordea Investment Management AB now owns 188,842 shares of the medical instruments supplier’s stock worth $11,850,000 after purchasing an additional 162,584 shares during the period. Institutional investors and hedge funds own 83.82% of the company’s stock.

In related news, SVP Giuseppe Accogli sold 28,641 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $67.00, for a total transaction of $1,918,947.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Jeanne K. Mason sold 33,350 shares of the firm’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $65.25, for a total value of $2,176,087.50. Following the sale, the senior vice president now directly owns 124,609 shares in the company, valued at approximately $8,130,737.25. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 5,061,991 shares of company stock worth $325,245,035. 0.05% of the stock is owned by corporate insiders.

A number of research firms have weighed in on BAX. Royal Bank of Canada reiterated a “hold” rating and issued a $66.00 target price on shares of Baxter International in a research note on Wednesday, November 22nd. Morgan Stanley increased their price target on Baxter International from $59.00 to $62.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 26th. Zacks Investment Research downgraded Baxter International from a “buy” rating to a “hold” rating in a research report on Monday, October 16th. Cowen reissued a “neutral” rating on shares of Baxter International in a research report on Friday, October 13th. Finally, BMO Capital Markets reissued a “buy” rating and set a $70.00 price target on shares of Baxter International in a research report on Friday, October 13th. Seven equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $68.64.

Baxter International Inc (BAX) traded up $1.00 on Friday, hitting $69.20. The stock had a trading volume of 4,383,000 shares, compared to its average volume of 3,319,092. Baxter International Inc has a fifty-two week low of $45.47 and a fifty-two week high of $69.65. The company has a quick ratio of 2.22, a current ratio of 2.80 and a debt-to-equity ratio of 0.37. The company has a market cap of $38,140.00, a P/E ratio of 37.41, a price-to-earnings-growth ratio of 2.05 and a beta of 0.69.

Baxter International (NYSE:BAX) last posted its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.05. Baxter International had a return on equity of 15.00% and a net margin of 9.88%. The business had revenue of $2.71 billion for the quarter, compared to the consensus estimate of $2.66 billion. During the same quarter in the prior year, the company earned $0.56 EPS. The business’s revenue was up 5.8% compared to the same quarter last year. equities analysts forecast that Baxter International Inc will post 2.43 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, January 2nd. Investors of record on Friday, December 1st were given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date was Thursday, November 30th. Baxter International’s payout ratio is currently 34.59%.

TRADEMARK VIOLATION WARNING: This news story was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://ledgergazette.com/2018/01/19/baxter-international-inc-bax-holdings-trimmed-by-bartlett-co-llc.html.

About Baxter International

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply